While the world focuses on new viruses and high-tech cures, typhoid fever – a centuries‑old bacterial infection – is quietly learning how to beat almost every antibiotic thrown at it, raising urgent questions for global health authorities.
An old disease that never really left
Typhoid fever sounds like something from a Victorian novel, not a 21st‑century threat. It is caused by the bacterium Salmonella enterica serovar Typhi, usually shortened to Salmonella Typhi. The germ has likely circulated in humans for thousands of years and is suspected by some historians of having killed Alexander the Great.
In high‑income countries, typhoid largely faded with the arrival of clean drinking water, sewage systems, and vaccines. For many doctors in Europe and North America, it is now a disease learned about for exams, not something they see on the ward.
Typhoid did not vanish; it retreated into the gaps of global infrastructure, thriving where clean water, sanitation and healthcare are weakest.
Those gaps are huge. Typhoid still infects millions of people each year, predominantly in South Asia, parts of sub‑Saharan Africa and some regions of Latin America. Children are hit hardest. Without treatment, the disease can cause intestinal perforation, sepsis and death.
How typhoid learned to outsmart antibiotics
The introduction of antibiotics in the mid‑20th century was supposed to finish typhoid off. It did not work out that way.
- Late 1940s: chloramphenicol becomes the first effective drug for typhoid.
- Within two years: resistant strains appear and spread.
- Later decades: resistance emerges against ampicillin, cotrimoxazole and then fluoroquinolones.
This pattern has repeated with almost every new drug class. Each time medicine rolls out a new treatment, Salmonella Typhi eventually finds a genetic workaround. Some of this resistance is carried on mobile bits of DNA that can move between bacteria. One lineage, known as haplotype H58, has become particularly notorious for its ability to accumulate and spread resistance genes, and is now dominant in many endemic regions.
Typhoid has become a moving target: every generation of antibiotics reshapes the population, favouring the most resistant strains.
What “XDR typhoid” means – and why it scares experts
In recent years, concern has focused on “extensively drug‑resistant” typhoid, often shortened to XDR typhoid. This term refers to strains that are resistant to five major types of antibiotics typically used against the infection.
➡️ What are the health benefits of cucumber?
➡️ How mental balance improves when expectations are simplified
➡️ “I’m over 60 and sitting hurt my back”: the posture fix that mattered most
➡️ 8 phrases deeply selfish people often say without realising it
➡️ No Vinegar, No Wax: The Easy Home Trick That Makes Hardwood Floors Shine Like New
➡️ If you’re over 65, this gentle daily habit supports better digestion
Since 2016, an XDR strain has taken hold in Pakistan. For many patients infected with this lineage, only a single oral drug, azithromycin, still works reliably. Hospital doctors can turn to certain injectable antibiotics, but those are costly, harder to deliver and not always available in rural settings.
The safety margin is therefore thin. Researchers have already identified mutations in a gene called acrB in Bangladesh that reduce the effectiveness of azithromycin. Those mutations have not yet merged with the XDR strain, but scientists warn it could take just one genetic “trade” – for example via plasmids or further mutation – for a fully untreatable form to emerge.
The nightmare scenario is a typhoid strain that shrugs off every widely available antibiotic, forcing a return to pre‑antibiotic medicine for this disease.
Typhoid doesn’t stay put: travel and global spread
Another reason experts are nervous: typhoid does not respect borders. People carry it when they migrate for work, visit family, or seek medical care. Air travel can move resistant strains between continents in less than a day.
Since the 1990s, public health groups have tracked resistant typhoid strains on every continent, including imported cases in Europe and North America. Most infections there still stem from travel to endemic regions, yet those imported cases put local health systems on alert and raise the risk of limited local transmission in under‑served communities.
Why some countries see typhoid and others do not
The geography of typhoid is not random; it maps almost perfectly onto inequality. Regions that invested heavily in treated water, sewerage and vaccination campaigns have seen the disease almost disappear. Others, forced to rely on cheap antibiotics as a substitute for infrastructure, live with constant circulation of the bacteria.
That strategy has a cost. In crowded cities with poor sanitation, contaminated water and patchy diagnostics, people are routinely given antibiotics “just in case” for fevers that may or may not be typhoid. Incomplete courses, low‑quality drugs and self‑medication all add fuel to the resistance fire.
| Factor | Effect on typhoid |
|---|---|
| Safe drinking water | Reduces transmission through faecal contamination |
| Sanitation and sewage | Stops the bacteria entering rivers and wells |
| Reliable diagnostics | Limits unnecessary antibiotic use |
| Vaccination coverage | Lowers the number of susceptible people and outbreaks |
Vaccines: a crucial, but partial shield
With antibiotics under pressure, vaccines have become a central part of the global response. The newest tools are typhoid conjugate vaccines, or TCVs, which link a piece of the bacterium to a carrier protein to boost the immune response.
One widely used product, Typbar‑TCV, was developed in India and has shown high protection levels in real outbreaks, including against XDR strains in Pakistan. Campaigns in cities such as Hyderabad reported around 97% effectiveness in preventing infection among vaccinated children.
Vaccination can sharply cut cases of typhoid, including resistant forms, breaking the cycle of constant antibiotic use that drives further resistance.
TCVs have several advantages: they can be given from as young as six months old, work with a single dose, and offer protection for several years. The World Health Organization now recommends them in countries where typhoid is a significant public health problem, especially where resistance is rising.
Still, vaccines alone cannot solve the structural roots of the disease. Without investment in water systems, sanitation and primary care, the bacteria will continue to circulate and look for new evolutionary tricks.
What rising resistance means for ordinary people
For families in high‑risk regions
In parts of South Asia, a simple fever can trigger difficult choices. Parents may not have access to reliable tests, so they buy whatever antibiotics the local pharmacy suggests. If the drug is fake, expired or the wrong type, the child may not improve – and the bacteria gain another opportunity to adapt.
In overloaded hospitals, doctors frequently treat suspected typhoid empirically, with little time for lab confirmation. As resistance rises, they are forced to reach for last‑line drugs that should be used sparingly, pushing costs higher and shrinking future options.
For travellers and residents of wealthy countries
People from the UK, US or Europe who visit relatives in endemic regions, work on humanitarian projects or go backpacking can bring typhoid home. Most recover with modern care, but resistant strains complicate treatment and increase the risk of severe disease.
Travel clinics already recommend typhoid vaccination and safe‑food habits for many destinations. As resistance worsens, there is likely to be greater emphasis on pre‑travel vaccines and rapid diagnosis for any fever after return.
Antibiotic resistance, briefly explained
Antibiotic resistance sounds abstract, but at its core it is simple evolution. When bacteria are exposed to a drug, most die. A few carry mutations that let them survive. Those survivors multiply, passing on their resistant traits. Over time, the drug stops working.
Typhoid adds an extra twist because it can acquire resistance genes from other bacteria through horizontal gene transfer. This is like copying and pasting a cheat code rather than slowly solving the puzzle from scratch.
Key ideas worth keeping in mind:
- Resistance does not make bacteria stronger in every way, but it makes them harder to treat.
- Once resistance spreads widely, rolling it back is extremely difficult.
- Every unnecessary antibiotic course gives bacteria one more training session against our drugs.
What a worst‑case typhoid future could look like
Public health modellers sketch a scenario where azithromycin fully fails against XDR typhoid. In that world, oral treatment would become unreliable in many communities. Patients would need injectable drugs in hospital, lengthening admissions and raising costs.
For rural families with limited transport or cash, that barrier could mean delayed care or no care at all. Outbreaks might last longer and become more deadly. Health systems already stretched by dengue, COVID‑19 and other infections would face yet another surge.
There are ways to avoid that outcome: scaling up TCV campaigns, upgrading water networks, regulating antibiotic sales and strengthening surveillance so that resistant strains are spotted early. Each step reduces the room typhoid has to manoeuvre.
For now, this old disease is sending a clear message. It never went away. It adapted. The question for health authorities is whether policy, infrastructure and drug development can adapt quickly enough in return.
